Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2022 | In vitro characterization of response to venetoclax in AL amyloidosis

Niels van Nieuwenhuijzen • 7 Sep 2022
ISA 2022
Amyloidosis Rare Diseases Venetoclax

Niels van Nieuwenhuijzen, MD, University Medical Center Utrecht, Utrecht, Netherlands, shares the results of a study investigating response to venetoclax in a hydrogel model of AL amyloidosis plasma cells, describing the features and advantages of this model. Overall, the study did not demonstrate a difference in response to venetoclax between t(11;14)-positive and negative amyloidosis plasma cells. This interview took place at the 2022 International Symposium on Amyloidosis (ISA) held in Heidelberg, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals